Travere Therapeutics Inc (NASDAQ: TVTX) is 87.54% higher on its value in year-to-date trading and has touched a low of $5.12 and a high of $20.33 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TVTX stock was last observed hovering at around $17.14 in the last trading session, with the day’s loss setting it -0.28%.
Currently trading at $16.86, the stock is -8.62% and -6.96% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.82 million and changing -1.63% at the moment leaves the stock 52.01% off its SMA200. TVTX registered 104.12% gain for a year compared to 6-month gain of 142.59%. The firm has a 50-day simple moving average (SMA 50) of $18.0891 and a 200-day simple moving average (SMA200) of $11.047575.
The stock witnessed a -3.05% loss in the last 1 month and extending the period to 3 months gives it a 11.95%, and is -9.74% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.84% over the week and 4.12% over the month.
Travere Therapeutics Inc (TVTX) has around 380 employees, a market worth around $1.47B and $203.45M in sales. Profit margin for the company is -172.78%. Distance from 52-week low is 229.30% and -17.07% from its 52-week high. The company has generated returns on investments over the last 12 months (-117.93%).
The EPS is expected to shrink by -161.54% this year
The shares outstanding are 87.03M, and float is at 85.74M with Short Float at 8.83%.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.64 million shares valued at $62.84 million. The investor’s holdings represent 9.8642 of the TVTX Shares outstanding. As of 2024-06-30, the second largest holder is ARMISTICE CAPITAL, LLC with 7.5 million shares valued at $61.65 million to account for 9.6774 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 7.37 million shares representing 9.5096 and valued at over $60.58 million, while VANGUARD GROUP INC holds 8.5416 of the shares totaling 6.62 million with a market value of $54.41 million.
Travere Therapeutics Inc (TVTX) Insider Activity
The most recent transaction is an insider sale by Calvin Sandra, the company’s SVP, CHIEF ACCOUNTING OFFICER. SEC filings show that Calvin Sandra sold 12,090 shares of the company’s common stock on Nov 25 ’24 at a price of $18.30 per share for a total of $0.22 million. Following the sale, the insider now owns 54927.0 shares.
Still, SEC filings show that on Oct 04 ’24, LYONS GARY A (Director) disposed off 40,000 shares at an average price of $14.73 for $0.59 million. The insider now directly holds 51,000 shares of Travere Therapeutics Inc (TVTX).
